Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer

Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Walentowicz, Pawel, Sadlecki, Pawel, Krintus, Magdalena, Sypniewska, Grazyna, Mankowska-Cyl, Aneta, Grabiec, Marek, Walentowicz-Sadlecka, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745840/
https://www.ncbi.nlm.nih.gov/pubmed/23983687
http://dx.doi.org/10.1155/2013/517239
_version_ 1782280740673683456
author Walentowicz, Pawel
Sadlecki, Pawel
Krintus, Magdalena
Sypniewska, Grazyna
Mankowska-Cyl, Aneta
Grabiec, Marek
Walentowicz-Sadlecka, Malgorzata
author_facet Walentowicz, Pawel
Sadlecki, Pawel
Krintus, Magdalena
Sypniewska, Grazyna
Mankowska-Cyl, Aneta
Grabiec, Marek
Walentowicz-Sadlecka, Malgorzata
author_sort Walentowicz, Pawel
collection PubMed
description Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer.
format Online
Article
Text
id pubmed-3745840
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37458402013-08-27 Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer Walentowicz, Pawel Sadlecki, Pawel Krintus, Magdalena Sypniewska, Grazyna Mankowska-Cyl, Aneta Grabiec, Marek Walentowicz-Sadlecka, Malgorzata Int J Endocrinol Research Article Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (P > 0.05). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer. Hindawi Publishing Corporation 2013 2013-07-28 /pmc/articles/PMC3745840/ /pubmed/23983687 http://dx.doi.org/10.1155/2013/517239 Text en Copyright © 2013 Pawel Walentowicz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Walentowicz, Pawel
Sadlecki, Pawel
Krintus, Magdalena
Sypniewska, Grazyna
Mankowska-Cyl, Aneta
Grabiec, Marek
Walentowicz-Sadlecka, Malgorzata
Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title_full Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title_fullStr Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title_full_unstemmed Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title_short Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
title_sort serum anti-müllerian hormone levels in patients with epithelial ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745840/
https://www.ncbi.nlm.nih.gov/pubmed/23983687
http://dx.doi.org/10.1155/2013/517239
work_keys_str_mv AT walentowiczpawel serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT sadleckipawel serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT krintusmagdalena serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT sypniewskagrazyna serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT mankowskacylaneta serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT grabiecmarek serumantimullerianhormonelevelsinpatientswithepithelialovariancancer
AT walentowiczsadleckamalgorzata serumantimullerianhormonelevelsinpatientswithepithelialovariancancer